Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB001 Recombinant Peptide Spray for Mild Recurrent Aphthous Ulcer
NCT06429566Phase 2Active, not recruiting
- Sponsor
- Zhejiang Echon Biopharm
- Start
- Jul 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GB001 in Recurrent aphthous stomatitis (RAS) (3 arms), sponsored by Zhejiang Echon Biopharm. Primary endpoints: Target ulcer healing rate at Day 6 and Subjects self-rated the time it took for irritation pain to disappear at Day 8. Started Jul 2023; status: active, not recruiting.
02
Drugs
GB001
03
Conditions
Recurrent aphthous stomatitis (RAS)
Beyond the preview
Go deeper on NCT06429566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429566.